Severe Combined Immunodeficiency (SCID) Screening in Arizona: Lessons Learned from the First 2 Years
Tóm tắt
The incidence of severe combined immunodeficiency (SCID) in the USA was reported as 1 in 58,000 live births. In Arizona, it was anticipated that newborn screening would identify two to four cases of SCID per year. This estimate did not consider ethnic nuances in Arizona, with higher percentages of Native American and Hispanic populations compared to national percentages. The true incidence of SCID and non-SCID T cell lymphopenia has not previously been reported in Arizona. A retrospective chart review was performed on all abnormal SCID newborn screening (NBS) tests in Arizona from January 1, 2018, to December 31, 2019, using data from the Arizona Department of Health Services and the Phoenix Children’s Hospital’s electronic medical record [IRB# 20–025]. Seven infants were diagnosed with SCID, yielding an incidence of 1 in 22,819 live births. Four of these infants had Artemis-type SCID. Thirteen infants were identified with an abnormal initial NBS which ultimately did not lead to a diagnosis of SCID. Four of these infants were diagnosed with congenital syndromes associated with T cell lymphopenia. Infants of Hispanic ethnicity were over-represented in this cohort. Over 2 years, NBS in Arizona confirmed an incidence more than 2.5 times that reported nationally. This increased incidence is likely reflective of Arizona’s unique population profile, with a higher percentage of Native American population. The findings in our non-SCID cohort are in alignment with previously published data, except for an increased percentage of infants of Hispanic/Latino ethnicity, possibly reflecting Arizona’s increased percentage of Hispanic/Latino population compared to the general US population.
Tài liệu tham khảo
Pai SY. Treatment of primary immunodeficiency with allogeneic transplant and gene therapy. Hematol Am Soc Hematol Educ Program. 2019;2019(1):457–65. https://doi.org/10.1182/hematology.2019000052.
Kohn DB, Hershfield MS, Puck JM, Aiuti A, Blincoe A, Gaspar HB, et al. Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency. J Allergy Clin Immunol. 2019;143(3):852–63. https://doi.org/10.1016/j.jaci.2018.08.024.
Charrier S, Lagresle-Peyrou C, Poletti V, Rothe M, Cédrone G, Gjata B, et al. Biosafety studies of a clinically applicable lentiviral vector for the gene therapy of Artemis-SCID. Mol Ther Methods Clin Dev. 2019;15:232–45. https://doi.org/10.1016/j.omtm.2019.08.014.
Chan A, Scalchunes C, Boyle M, Puck JM. Early vs. delayed diagnosis of severe combined immunodeficiency: a family perspective survey. Clin Immunol. 2011;138(1):3–8. https://doi.org/10.1016/j.clim.2010.09.010.
Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, et al. Transplantation outcomes for severe combined immunodeficiency, 2000–2009. N Engl J Med. 2014;371(5):434–46. https://doi.org/10.1056/NEJMoa1401177.
Routes J, Verbsky J. Newborn screening for severe combined immunodeficiency. Curr Allergy Asthma Rep. 2018;18(6):34. https://doi.org/10.1007/s11882-018-0783-9.
Newborn screening for severe combined immunodeficiency: a summary of the evidence and Advisory Committee decision. Report date 29 April 2009. Accessed November 2, 2020. https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominatoins/scid-27-june-2018.pdf.
Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729–38. https://doi.org/10.1001/jama.2014.9132.
Services ADoH. Population health and vital statistics. Available from: https://pub.azdhs.gov/health-stats/menu/info/trend/index.php?pg=births. Accessed 10 Jan 2021
Wright BL, Miller H, Adams R, Daines M Newborn screening for severe combined immunodeficiency in Arizona. https://azdhs.gov/documents/preparedness/state-laboratory/newborn-screening/scid-event/nbs-scid-poster.pdf2016 [updated 2016. Arizona Department of Health]. Accessed 10 Jan 2021
Li L, Moshous D, Zhou Y, Wang J, Xie G, Salido E, et al. A founder mutation in Artemis, an SNM1-like protein, causes SCID in Athabascan-speaking Native Americans. J Immunol. 2002;168(12):6323–9. https://doi.org/10.4049/jimmunol.168.12.6323.
Kwan A, Hu D, Song M, Gomes H, Brown DR, Bourque T, et al. Successful newborn screening for SCID in the Navajo Nation. Clin Immunol. 2015;158(1):29–34. https://doi.org/10.1016/j.clim.2015.02.015.
Kwan A, Church JA, Cowan MJ, Agarwal R, Kapoor N, Kohn DB, et al. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years. J Allergy Clin Immunol. 2013;132(1):140–50. https://doi.org/10.1016/j.jaci.2013.04.024.
United States Census Bureau QuickFacts [Internet]. 2020 [updated 2020 Dec 10, cited 2021 Jan 10]. Available from: https://www.census.gov/quickfacts/fact/table/AZ,US/RHI325219.
Shearer WT, Rosenblatt HM, Gelman RS, Oyomopito R, Plaeger S, Stiehm ER, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol. 2003;112(5):973–80. https://doi.org/10.1016/j.jaci.2003.07.003.
Bosticardo M, Yamazaki Y, Cowan J, Giardino G, Corsino C, Scalia G, et al. Heterozygous FOXN1 variants cause low TRECs and severe T cell lymphopenia, revealing a crucial role of FOXN1 in supporting early thymopoiesis. Am J Hum Genet. 2019;105(3):549–61. https://doi.org/10.1016/j.ajhg.2019.07.014.
Dorsey MJ, Puck JM. Newborn screening for severe combined immunodeficiency in the United States: lessons learned. Immunol Allergy Clin North Am. 2019;39(1):1–11. https://doi.org/10.1016/j.iac.2018.08.002.
Bittles AH, Black ML. Evolution in health and medicine Sackler colloquium: consanguinity, human evolution, and complex diseases. Proc Natl Acad Sci USA. 2010;107(Suppl 1):1779–86. https://doi.org/10.1073/pnas.0906079106.
Heimall J, Logan BR, Cowan MJ, Notarangelo LD, Griffith LM, Puck JM, et al. Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study. Blood. 2017;130(25):2718–27. https://doi.org/10.1182/blood-2017-05-781849.
Puck JM. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia. Immunol Rev. 2019;287(1):241–52. https://doi.org/10.1111/imr.12729.
Mallott J, Kwan A, Church J, Gonzalez-Espinosa D, Lorey F, Tang LF, et al. Newborn screening for SCID identifies patients with ataxia telangiectasia. J Clin Immunol. 2013;33(3):540–9. https://doi.org/10.1007/s10875-012-9846-1.
Kuo CY, Garcia-Lloret MI, Slev P, Bohnsack JF, Chen K. Profound T-cell lymphopenia associated with prenatal exposure to purine antagonists detected by TREC newborn screening. J Allergy Clin Immunol Pract. 2017;5(1):198–200. https://doi.org/10.1016/j.jaip.2016.09.028.